Repatha and Lung neoplasm malignant - a phase IV clinical study of FDA data

Summary:

Lung neoplasm malignant is reported as a side effect among people who take Repatha (evolocumab), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Plavix, and have Hyperlipidaemia.

The phase IV clinical study analyzes which people have Lung neoplasm malignant when taking Repatha. It is created by eHealthMe based on reports of 155,838 people who have side effects when taking Repatha from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,258 Repatha users. Check the latest studies of Repatha.

What is Lung neoplasm malignant?

Lung neoplasm malignant (cancer tumour of lung) is found to be associated with 1,146 drugs and 928 conditions by eHealthMe. Check the latest studies of Lung neoplasm malignant.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

155,838 people reported to have side effects when taking Repatha.
Among them, 61 people (0.04%) have Lung neoplasm malignant.

Could Repatha cause Lung neoplasm malignant?

Among these 61 people:

How long have people been on Repatha when they have Lung neoplasm malignant? *

What is the gender of people who have Lung neoplasm malignant when taking Repatha? *

female: 58.93 %
male: 41.07 %

What is the age of people who have Lung neoplasm malignant when taking Repatha? *

What are other drugs people take besides Repatha? *

What are other side effects people have besides Lung neoplasm malignant? *

Arterial Occlusive Disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked): 3 people, 4.92%
Adverse Drug Reaction: 2 people, 3.28%
Memory Loss: 2 people, 3.28%
Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 3.28%
Fall: 2 people, 3.28%
Lymphoedema (localized fluid retention and tissue swelling): 2 people, 3.28%
Pain In Extremity: 2 people, 3.28%
Colon Cancer: 2 people, 3.28%
Dyspnea (difficult or laboured breathing): 2 people, 3.28%
Breast Cancer: 2 people, 3.28%

What are the existing conditions these people have? *

Hyperlipidaemia (presence of excess lipids in the blood): 9 people, 14.75%
Stress And Anxiety: 5 people, 8.20%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 8.20%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 8.20%
Cardiac Disorder: 5 people, 8.20%
Depression: 5 people, 8.20%
Pain: 4 people, 6.56%
Atherosclerosis (disorder of the arteries): 3 people, 4.92%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 4.92%
Diabetes: 2 people, 3.28%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and have Lung neoplasm malignant?

- Check whether Lung neoplasm malignant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Repatha:

Repatha (156,258 reports)

Browse all side effects of Repatha:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lung neoplasm malignant:

Lung neoplasm malignant (1,146 drugs)

Browse all the conditions that are associated with Lung neoplasm malignant:

Lung neoplasm malignant (928 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on evolocumab (the active ingredients of Repatha) and Repatha (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.